Showing results (21-30 of 183) with videos related to
Sort By:
Pageof 19
Journal of Molecular Medicine (Berlin, Germany)|September 19, 2003
BRCA1 and p53: compensatory roles in DNA repairAnne-Renee Hartman, James M FordScientific Reports|October 21, 2025
PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSamyuktha Suresh, Lisa McPherson, James M FordCancer Research|December 4, 2002
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancerElizabeth Alli, Judy Bash-Babula, Jin-Ming Yang, et al.Research Square|February 26, 2024
Repurposing mebendazole against triple-negative breast cancer leptomeningeal diseaseAdrian Rodrigues, Sophia B Chernikova, Yuelong Wang, et al.Cancer Letters|November 13, 2013
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cellsLisa A McPherson, Yuqiao Shen, James M FordBreast Cancer Research and Treatment|October 30, 2013
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer riskShaveta Vinayak, Erich J Schwartz, Kristin Jensen, et al.Journal of Neuro-Oncology|April 2, 2024
Repurposing mebendazole against triple-negative breast cancer CNS metastasisAdrian J Rodrigues, Sophia B Chernikova, Yuelong Wang, et al.Oncotarget|April 17, 2017
Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancersKedar Hastak, Steven Bhutra, Renate Parry, et al.Cancer|September 19, 2008
Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgeryRobin M Cisco, James M Ford, Jeffrey A NortonCurrent Opinion in Obstetrics & Gynecology|December 16, 2014
Next-generation sequencing for hereditary breast and gynecologic cancer risk assessmentAllison W Kurian, Kerry E Kingham, James M FordPageof 19